Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Chronic Heart Failure

Free Subscription Articles published in J Cardiovasc Pharmacol Retrieve available abstracts of 28 articles: HTML format

Single Articles

November 2021
1. VIDER E, Sapir R, Mosseri E, Gavioli E, et al
   Current perspectives of the use of Sodium Glucose Transport-2 Inhibitors for patients with heart failure and chronic kidney disease.
   J Cardiovasc Pharmacol. 2021 Nov 3. pii: 00005344-900000000-98119.
   PubMed     Abstract available
   
   
   
2. FERNANDES C, Antonio N, Marinho V, Milner J, et al
   Digoxin in patients with advanced heart failure and sinus rhythm submitted to cardiac resynchronization therapy- is there any benefit?
   J Cardiovasc Pharmacol. 2021 Nov 3. pii: 00005344-900000000-98116.
   PubMed     Abstract available
   
   
   
3. AMRITPHALE A
   Right Heart Failure Management: the Achilles heel.
   J Cardiovasc Pharmacol. 2021 Nov 3. pii: 00005344-900000000-98115.
   PubMed    
   
   
   October 2021
4. MASARONE D, Melillo E, Errigo V, Martucci ML, et al
   Haemodynamic Effects of Levosimendan in Outpatients with Advanced Heart Failure: An Echocardiographic Pilot Study.
   J Cardiovasc Pharmacol. 2021 Oct 23. pii: 00005344-900000000-98126.
   PubMed     Abstract available
   
   
   
5. YANG Y, Shen C, Lu J, Fu G, et al
   Sacubitril/valsartan in the treatment of right ventricular dysfunction in patients with heart failure with reduced ejection fraction: a real-world study.
   J Cardiovasc Pharmacol. 2021 Oct 21. pii: 00005344-900000000-98124.
   PubMed     Abstract available
   
   
   July 2021
6. SHRESTHA DB, Budhathoki P, Sedhai YR, Karki P, et al
   SGLT-2 inhibitors in heart failure: An updated systematic review and meta-analysis of 13 randomized clinical trials including 14618 patients with heart failure.
   J Cardiovasc Pharmacol. 2021 Jul 9. pii: 00005344-900000000-98175.
   PubMed     Abstract available
   
   
   
7. DEL BUONO MG, Damonte JI, Trankle CR, Bhardwaj H, et al
   Sacubitril/Valsartan for the prevention and treatment post-infarction heart failure: ready to use?
   J Cardiovasc Pharmacol. 2021 Jul 2. pii: 00005344-900000000-98179.
   PubMed    
   
   
   June 2021
8. ADIE SK, Ketcham SW, Abdul-Aziz AA, Thomas MP, et al
   Characteristics of heart failure patients with or without hypotension when transitioning from nitroprusside to sacubitril-valsartan.
   J Cardiovasc Pharmacol. 2021 Jun 21. pii: 00005344-900000000-98191.
   PubMed     Abstract available
   
   
   May 2021
9. NANDKEOLYAR S, Ryu R, Mohammed A, Cordero-Caban K, et al
   A Review of Inotropes and Inopressors for Effective Utilization in Patients with Acute Decompensated Heart Failure.
   J Cardiovasc Pharmacol. 2021 May 28. pii: 00005344-900000000-98208.
   PubMed     Abstract available
   
   
   April 2021
10. LONG YX, Cui DY, Kuang X, Hu S, et al
    Effect of Levosimendan on Ventricular Systolic and Diastolic Functions in Heart Failure Patients: A Meta-analysis of Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2021 Apr 5. pii: 00005344-900000000-98238.
    PubMed     Abstract available
    
    
    February 2021
11. HAN Y, Hua S, Chen Y, Yang W, et al
    Circulating PGLYRP1 levels as a potential biomarker for coronary artery disease and heart failure.
    J Cardiovasc Pharmacol. 2021 Feb 18. pii: 00005344-900000000-98269.
    PubMed     Abstract available
    
    
    December 2020
12. RERICK L, Elston C, Kester J, Montepara C, et al
    Evaluation of sacubitril/valsartan initiation in outpatient heart failure patients.
    J Cardiovasc Pharmacol. 2020 Dec 1. doi: 10.1097/FJC.0000000000000966.
    PubMed     Abstract available
    
    
    November 2020
13. WOHLFORD GF, Van Tassell BW, Billingsley HE, Kadariya D, et al
    A Phase IB, Randomized, Double-Blinded, Dose Escalation, Single Center, Repeat-Dose Safety and Pharmacodynamics Study of the Oral NLRP3 Inhibitor Dapansutrile in Subjects with NYHA II-III Systolic Heart Failure.
    J Cardiovasc Pharmacol. 2020 Nov 17. doi: 10.1097/FJC.0000000000000931.
    PubMed     Abstract available
    
    
    
14. GAO D, David C, Rosa MM, Costa J, et al
    The risk of mortality associated with opioid use in patients with acute heart failure: systematic review and meta-analysis.
    J Cardiovasc Pharmacol. 2020 Nov 17. doi: 10.1097/FJC.0000000000000954.
    PubMed     Abstract available
    
    
    
15. GIUSEPPE DEL BUONO M, Crea F, Versaci F, Biondi-Zoccai G, et al
    NLRP3 inflammasome: a new promising therapeutic target to treat heart failure.
    J Cardiovasc Pharmacol. 2020 Nov 2. doi: 10.1097/FJC.0000000000000946.
    PubMed    
    
    
    October 2020
16. BERNIER TD, Buckley LF
    Cardiac Myosin Activation for the Treatment of Systolic Heart Failure.
    J Cardiovasc Pharmacol. 2020 Oct 30. doi: 10.1097/FJC.0000000000000929.
    PubMed     Abstract available
    
    
    
17. HU J, Wu Y, Zhou X, Wang X, et al
    Beneficial Effects of Sacubitril/Valsartan at Low Doses in an Asian Real-World Heart Failure Population.
    J Cardiovasc Pharmacol. 2020;76:445-451.
    PubMed     Abstract available
    
    
    August 2020
18. LI C, Xia W, Wang L, Zhang J, et al
    Effect of renal denervation on cardiac function and inflammatory factors in heart failure after myocardial infarction.
    J Cardiovasc Pharmacol. 2020 Aug 24. doi: 10.1097/FJC.0000000000000899.
    PubMed     Abstract available
    
    
    July 2020
19. JIA K, Dai Y, Liu A, Li X, et al
    The senolytic agent navitoclax inhibits angiotensin II-induced heart failure in mice Navitoclax inhibits heart failure.
    J Cardiovasc Pharmacol. 2020 Jul 10. doi: 10.1097/FJC.0000000000000878.
    PubMed     Abstract available
    
    
    
20. PAPP Z, Agostoni P, Alvarez J, Bettex D, et al
    Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use.
    J Cardiovasc Pharmacol. 2020;76:4-22.
    PubMed     Abstract available
    
    
    June 2020
21. SHEN JL, Xie XJ
    Insight into the Pro-inflammatory and Pro-Fibrotic Role of Macrophage in Heart Failure with Preserved Ejection Fraction.
    J Cardiovasc Pharmacol. 2020 Jun 4. doi: 10.1097/FJC.0000000000000858.
    PubMed     Abstract available
    
    
    
22. DENG T, Wei Z, Gael A, Deng X, et al
    Higenamine Improves Cardiac and Renal Fibrosis in Rats With Cardiorenal Syndrome via ASK1 Signaling Pathway.
    J Cardiovasc Pharmacol. 2020;75:535-544.
    PubMed     Abstract available
    
    
    February 2020
23. KELLY J, Cheng J, Malloy R, Lupi K, et al
    Comparison of positive inotropic agents in the management of acute decompensated heart failure.
    J Cardiovasc Pharmacol. 2020 Feb 20. doi: 10.1097/FJC.0000000000000811.
    PubMed     Abstract available
    
    
    January 2020
24. CHOU CC, Lee HL, Huang YC, Wo HT, et al
    Single Bolus Rosuvastatin Accelerates Calcium Uptake and Attenuates Conduction Inhomogeneity in Failing Rabbit Hearts With Regional Ischemia-Reperfusion Injury.
    J Cardiovasc Pharmacol. 2020;75:64-74.
    PubMed     Abstract available
    
    
    December 2019
25. LTEIF C, Arwood MJ, Kansal M, Cavallari LH, et al
    Beta-blocker Dose Stratifies Mortality Risk in a Racially Diverse Heart Failure Population.
    J Cardiovasc Pharmacol. 2019 Dec 31. doi: 10.1097/FJC.0000000000000779.
    PubMed     Abstract available
    
    
    November 2019
26. DEL BUONO MG, Bonaventura A, Vecchie A, Wohlford GF, et al
    Sacubitril-Valsartan for the treatment of heart failure: Time for a paragon?
    J Cardiovasc Pharmacol. 2019 Nov 29. doi: 10.1097/FJC.0000000000000782.
    PubMed    
    
    
    February 2019
27. VICENT L, Esteban-Fernandez A, Gomez-Bueno M, De-Juan J, et al
    Sacubitril/Valsartan in Daily Clinical Practice: Data From a Prospective Registry.
    J Cardiovasc Pharmacol. 2019;73:118-124.
    PubMed     Abstract available
    
    
    January 2019
28. HERPAIN A, Bouchez S, Girardis M, Guarracino F, et al
    Use of Levosimendan in Intensive Care Unit Settings: An Opinion Paper.
    J Cardiovasc Pharmacol. 2019;73:3-14.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Chronic Heart Failure is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: